Adlai Nortye

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Adlai Nortye including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Adlai Nortye please access flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Adlai Nortye including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Adlai Nortye please access flcube.com

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis
CompanyDrug

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Bio‑Thera Solutions, Ltd. (SHA: 688177) announced that China's National Medical Products Administration (NMPA) has approved the Marketing Authorization Application for its Secukinumab Injection (BAT2306), indicated for the treatment of psoriasis,…

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer's Treatment Access

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer’s Treatment Access

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
CompanyDeals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

CompanyDrug

Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC

Aosaikang Licenses Adlai Nortye's Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
CompanyDeals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

CompanyDeals

Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million